Bioanalysis of Small Molecules and Generics
KYMOS specialises in world-class bioanalysis of small molecules from fast in vivo and in vitro ADMET screenings to preclinical toxicokinetic, bioavailability and pharmacokinetic studies, drug-drug interaction studies as well as clinical trials including first in man and dose escalation studies. We are a GLP-certified and GCP compliant multinational CRO with broad experience working with large generic companies in need of full bioequivalence studies, and small biotech innovators carrying out basic R&D. We also work with animal health firms to carry out residue depletion studies. Our experienced team can support you in these specialist areas:
PRECLINICAL , CLINICAL AND BIOEQUIVALENCE STUDIES
Our bioanalysis experts are experienced in the comprehensive management of preclinical and clinical bioanalytical studies from phases I to IV as well as bioequivalences; offering end-to-end service from IMPD review to final reporting. We work in alliance with reputed European preclinical and clinical centers following EMA/FDA guidelines and operating with most animal models including rats, mice, rabbits, minipigs, cats, dogs, non-human primates, swine, cattle, sheep, poultry and horses. High-quality standards, narrow timelines and competitive prices are key elements for our delivery.
Our experts can transfer existing bioanalytical methods and have a long list of validated methods offering the clients the opportunity of directly analyzing their samples thereby saving time and money. If one is not available, we can develop and validate the method free of charge in a timely manner. We are fully coordinated with our alliance partners to provide One Stop Shop services in the following areas:
